(Q34182242)

31 July 2017

1 reference

title

The new atypical antipsychotics: a review of pharmacoeconomic studies (English)

1 reference

31 July 2017

Revicki DA

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

1

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

249-260

1 reference

Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.249

Measuring quality of life in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.249

Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.249

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.249

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.249

Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.249

Effects of risperidone therapy on the use of mental health care resources in Salt Lake County, Utah.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.249

Olanzapine. A pharmacoeconomic review of its use in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.249

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.249

Issues in the design of studies for the economic evaluation of new atypical antipsychotics: the ESTO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.249

Risperidone versus haloperidol: II. Cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.249

Hospitalization Rates Among Clozapine-Treated Patients: A Prospective Cost-Benefit Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.249

21 January 2018

Identifiers

DOI

10.1517/14656566.1.2.249

1 reference

release_ri7hvtbnhfbbfddxublwp3rraq

31 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ri7hvtbnhfbbfddxublwp3rraq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference